HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 41 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $5,000 | – | 1,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 5,790,269 | $3,848,000 | 3.74% |
| PERKINS CAPITAL MANAGEMENT INC | 2,353,153 | $1,564,000 | 1.35% |
| Diametric Capital, LP | 269,822 | $179,000 | 0.15% |
| Nantahala Capital Management | 5,000,000 | $3,323,000 | 0.12% |
| Sio Capital Management, LLC | 300,000 | $199,000 | 0.06% |
| Cowen Prime Services LLC | 100,000 | $66,000 | 0.03% |
| Fondren Management LP | 40,375 | $27,000 | 0.02% |
| Kalos Management, Inc. | 66,900 | $46,000 | 0.02% |
| Alyeska Investment Group, L.P. | 1,387,665 | $922,000 | 0.01% |
| Hayden Royal, LLC | 12,000 | $8,000 | 0.01% |